Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Juli 2019 09:02 ET | Quelle: Salarius Pharmaceuticals

Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell

HOUSTON, July 29, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that President...
24. Juli 2019 16:05 ET | Quelle: Salarius Pharmaceuticals

Salarius Pharmaceuticals Successfully Monetizes Legacy Consumer Product

HOUSTON, July 24, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it completed...
22. Juli 2019 08:05 ET | Quelle: Salarius Pharmaceuticals

Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor Targeting Epigenetics in Patients with Advanced Solid Tumors

HOUSTON, July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it has...
22. Juli 2019 08:00 ET | Quelle: Salarius Pharmaceuticals

Salarius Pharmaceuticals Announces Closing of Strategic Merger with Flex Pharma

HOUSTON, July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that Salarius...

Vorherige Seite